Theravance Biopharma, Inc.
DE ˙ DB ˙ KYG8807B1068
13,90 € ↑0,30 (2,21%)
2026-06-05
DEL PRIS
SecurityDE:0TB / Theravance Biopharma, Inc.
InstitutionPDT Partners, LLC
Latest Disclosed Ownership33,796 shares
Latest Disclosed Value $ 548,509
PDT Partners, LLC reports 63.49% decrease in ownership of 0TB / Theravance Biopharma, Inc.

On May 15, 2026 - PDT Partners, LLC filed a 13F-HR form disclosing ownership of 33,796 shares of Theravance Biopharma, Inc. (DE:0TB) valued at $446,107 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 92,557 shares of Theravance Biopharma, Inc.. This represents a change in shares of -63.49% during the quarter. The current value of the position is $469,764 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 33,796 -58,761 -63.49 549 -68.34 0.0325
2026-02-17 2025-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 92,557 -17,152 -15.63 1,732 8.12 0.1123
2025-11-17 2025-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 109,709 -10,618 -8.82 1,602 20.65 0.1010
2025-08-14 2025-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 120,327 31,750 35.84 1,327 67.97 0.0751
2025-05-15 2025-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 88,577 50,901 135.10 791 123.16 0.0562
2025-02-14 2024-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 37,676 -49,501 -56.78 355 -49.57 0.0314
2024-11-14 2024-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 87,177 20,738 31.21 703 24.69 0.0623
2024-08-15 2024-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 66,439 0 0.00 563 -5.38 0.0533
2024-05-15 2024-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 66,439 34,016 104.91 596 63.46 0.0563
2024-02-14 2023-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 32,423 -49,035 -60.20 364 -48.15 0.0403
2023-11-14 2023-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 81,458 -700 -0.85 703 -17.41 0.0887
2023-08-14 2023-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 82,158 -203 -0.25 850 -4.82 0.1170
2023-05-15 2023-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 82,361 39 0.05 894 -3.25 0.1211
2023-02-14 2022-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 82,322 664 0.81 924 11.47 0.1495
2022-11-14 2022-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 81,658 -74,473 -47.70 828 -41.48 0.1253
2022-08-15 2022-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 156,131 -36,570 -18.98 1,415 -23.18 0.1248
2022-05-16 2022-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 192,701 81,322 73.01 1,842 49.63 0.1586
2022-02-14 2021-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 111,379 111,379 1,231 0.0938
2021-05-17 2021-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 0 -54,522 -100.00 0 -100.00
2021-02-16 2020-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 54,522 -11,539 -17.47 969 -0.82 0.0655
2020-11-16 2020-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 66,061 41,447 168.39 977 88.97 0.0645
2020-08-14 2020-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 24,614 24,614 517 0.0352
2016-02-16 2015-12-31 13F THERAVANCE BIOPHARMA COM G8807B106 0 -17,683 -100.00 0 -100.00
2015-11-16 2015-09-30 13F THERAVANCE BIOPHARMA COM G8807B106 17,683 -25,244 -58.81 194 -65.30 0.0043
2015-08-14 2015-06-30 13F THERAVANCE BIOPHARMA COM G8807B106 42,927 26,534 161.86 559 96.83 0.0146
2015-05-15 2015-03-31 13F THERAVANCE BIOPHARMA COM G8807B106 16,393 16,393 284 0.0073
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.